Further Sales. Licensee may continue to sell its remaining inventory of the Licensed Product for a period of *** from the effective date of such termination, subject to the payment of royalties pursuant to Section 8.7. Licensee covenants that promptly after such *** period it and its Affiliates and former Sublicensees hereunder shall cease to sell, and thereafter shall not sell, any Licensed Products or Licensed Molecules.
Further Sales. To the extent the Company, the Control Stockholder and the other Stockholders do not exercise their rights under Sections 3.2, or 3.3 with respect to the sale of Stock subject to the Notice, the Seller may, not later than one hundred twenty (120) days following the first delivery to the Company and the other Stockholders of the Notice, conclude a Transfer of the Stock covered by the Notice and (i) in the case of Section 3.2, not elected to be purchased by the Company or the Stockholders on terms and conditions no less favorable to the Seller than those described in the Notice or (ii) in the case of Section 3.3, not excluded from the Transfer by virtue of the participation therein by Co-Sale Stockholders on the terms and conditions set forth in the Notice. Any proposed Transfer on terms and conditions less favorable to the Seller than those described in the Notice (in the case of a Transfer subject to Section 3.2) or more favorable to the Seller than those described in the Notice (in the case of a Transfer subject to Section 3.3) or any proposed transfer of any Stock by the Seller after such one hundred twenty day period, shall again be subject to the co-sale rights and rights of first refusal of the Stockholders and shall require compliance by the Seller with the procedures described in this Section 3. Notwithstanding the foregoing, no Transfer of the Stock shall be effective unless such transferee agrees to be bound by the terms of this Agreement as a Stockholder.
Further Sales. To the extent the Company, First Reserve and the Co-Sale Stockholders do not exercise their rights under Sections 3.2 or 3.3 with respect to the sale of Stock subject to the Notice or the Final Notice, the Seller may, not later than sixty (60) days following delivery to the Company and the Stockholders of the Final Notice, conclude a transfer of the Stock covered by the Final Notice on terms and conditions equal to those described in the Final Notice. Any proposed transfer on terms and conditions other than those described in the Final Notice or any proposed transfer of any Stock by the Seller after such sixty day period shall again be subject to the co-sale rights and first refusal rights of the Stockholders and shall require compliance by the Seller with the procedures described in this Section 3. Notwithstanding the foregoing, no transfer of the Stock shall be effective unless such transferee agrees to be bound by the terms of this Agreement as a Stockholder.
Further Sales. To the extent the Company, the Sponsors and the other Stockholders do not exercise their rights under Sections 4.2 with respect to the sale of Stock subject to the Notice, the Seller may, not later than one hundred twenty (120) days following the
Further Sales. The Company may, from time to time, without the consent of the Noteholder, create and sell additional notes having the same terms and conditions of this Senior Note in all respects (except for the issue date, issue price and initial Interest Payment Date) so that such additional notes would form a single series with the Senior Notes and rank equally and ratably with the Senior Notes or would form a new series. No additional Senior Notes may be issued if any Event of Default has occurred and is continuing with respect to the Senior Notes.
Further Sales. In the event of any such termination, Roche may continue to sell its remaining inventory of the applicable Reverted Product for a period of six (6) months from the effective date of such termination, subject to the payment of royalties pursuant to Section 8.1. Roche covenants that promptly after such six (6) month period it and its Affiliates and former Sublicensees hereunder shall cease to sell, and thereafter shall not sell, any Reverted Product for the Licensed Field.
Further Sales. If this Agreement is terminated for any reason other than termination by Licensor for Licensee’s material breach pursuant to Section 9.4 (Termination for Cause) or by Licensor for a Challenge pursuant to Section 9.5 (Termination for Patent Challenges), then for a period of up to [*] after the effective date of such termination, (a) Licensee or its Affiliate or Sublicensee will have the continued right to sell the Licensed Products in such country from its inventory and the obligation to comply with the terms of this Agreement in connection with such Commercialization, and (b) Licensee’s and its Affiliates’ and Sublicensees’ obligations under this Agreement with respect to all such Licensed Product that Licensee or its Affiliates or Sublicensees sell, including the obligation to remit Royalties to Licensor hereunder, will continue in full force and effect during such period.
Further Sales. In the event of any such termination (other than termination for Licensee’s material breach), Licensee may continue to sell its remaining inventory of the Licensed Product for a period of [***] months from the effective date of such termination, subject to the payment of royalties pursuant to Section 8.5. Licensee covenants that promptly after such [***] month period it and its Affiliates and former sublicensees hereunder shall cease to sell, and thereafter shall not sell, any Licensed Products.
Further Sales. In the event of any such termination, Metabolex may continue to sell its remaining inventory of the PPAR-d Product or PPAR-d Compound for a period of [*] from the effective date of such termination, subject to the payment of royalties pursuant to Section 4.1. Metabolex covenants that promptly after such [*] period it and its Affiliates and former sublicensees hereunder shall cease to sell, and thereafter shall not sell, any PPAR-d Products or PPAR-d Compounds.
Further Sales. In the event of any such termination, Metabolex may continue to sell its remaining inventory of the PPAR-d Product or PPAR-d Compound for a period of [*] from the effective date of such termination, subject to the payment of royalties pursuant to Section 4.1. Metabolex covenants that promptly after such [*] period it and its Affiliates and former sublicensees hereunder shall cease to sell, and thereafter shall not sell, any PPAR-d Products or PPAR-d Compounds. [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
